APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Schistosomiasis

Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.

Selected research

Market Structure

Global Drugs for Schistosomiasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

25 December 2025181 pages

Choose your research edition.

Industry ResearchDrugs for Schistosomiasis Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Schistosomiasis Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Drugs for Schistosomiasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Schistosomiasis Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Schistosomiasis Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.

Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma and Taj Pharmaceuticals are the main manufacturers of drugs for Schistosomiasis.

East Africa is the largest region of drugs for Schistosomiasis, whose market share is about 24%,

Read the full market overview

Followed by West Africa(20%).

This report provides an overview of the global Drugs for Schistosomiasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Schistosomiasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Schistosomiasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for Schistosomiasis market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for Schistosomiasis Segment by Company

Shin Poong

Merck

Bayer

EIPICO

Chandra Bhagat Pharma

Taj Pharmaceuticals

Drugs for Schistosomiasis Segment by Type

Praziquantel

Oxamniquine

Other

Drugs for Schistosomiasis Segment by Application

S. haematobium

S. mansoni

S. japonicum

S. mekongi

S. intercalatum

Drugs for Schistosomiasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Schistosomiasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Schistosomiasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Schistosomiasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for Schistosomiasis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs for Schistosomiasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Drugs for Schistosomiasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Drugs for Schistosomiasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Drugs for Schistosomiasis Industry Trends Table 2. Drugs for Schistosomiasis Industry Drivers Table 3. Drugs for Schistosomiasis Industry Opportunities and Challenges Table 4. Drugs for Schistosomiasis Industry Restraints Table 5. Global Drugs for Schistosomiasis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Drugs for Schistosomiasis Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Drugs for Schistosomiasis Sales by Manufacturers (M Units) & (2021-2026) Table 8. Global Drugs for Schistosomiasis Sales Market Share by Manufacturers Table 9. Global Drugs for Schistosomiasis Average Sales Price (USD/K Units) of Manufacturers (2021-2026) Table 10. Global Drugs for Schistosomiasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Drugs for Schistosomiasis Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Drugs for Schistosomiasis Manufacturers, Product Type & Application Table 13. Global Drugs for Schistosomiasis Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for Schistosomiasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Praziquantel Table 17. Major Manufacturers of Oxamniquine Table 18. Major Manufacturers of Other Table 19. Global Drugs for Schistosomiasis Sales by Type 2021 VS 2025 VS 2032 (M Units) Table 20. Global Drugs for Schistosomiasis Sales by Type (2021-2026) & (M Units) Table 21. Global Drugs for Schistosomiasis Sales by Type (2027-2032) & (M Units) Table 22. Global Drugs for Schistosomiasis Sales Market Share by Type (2021-2026) Table 23. Global Drugs for Schistosomiasis Sales Market Share by Type (2027-2032) Table 24. Global Drugs for Schistosomiasis Revenue by Type 2021 VS 2025 VS 2032 (M Units) Table 25. Global Drugs for Schistosomiasis Revenue by Type (2021-2026) & (M Units) Table 26. Global Drugs for Schistosomiasis Revenue by Type (2027-2032) & (M Units) Table 27. Global Drugs for Schistosomiasis Revenue Market Share by Type (2021-2026) Table 28. Global Drugs for Schistosomiasis Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of S. haematobium Table 30. Major Manufacturers of S. mansoni Table 31. Major Manufacturers of S. japonicum Table 32. Major Manufacturers of S. mekongi Table 33. Major Manufacturers of S. intercalatum Table 34. Global Drugs for Schistosomiasis Sales by Application 2021 VS 2025 VS 2032 (M Units) Table 35. Global Drugs for Schistosomiasis Sales by Application (2021-2026) & (M Units) Table 36. Global Drugs for Schistosomiasis Sales by Application (2027-2032) & (M Units) Table 37. Global Drugs for Schistosomiasis Sales Market Share by Application (2021-2026) Table 38. Global Drugs for Schistosomiasis Sales Market Share by Application (2027-2032) Table 39. Global Drugs for Schistosomiasis Revenue by Application 2021 VS 2025 VS 2032 (M Units) Table 40. Global Drugs for Schistosomiasis Revenue by Application (2021-2026) & (M Units) Table 41. Global Drugs for Schistosomiasis Revenue by Application (2027-2032) & (M Units) Table 42. Global Drugs for Schistosomiasis Revenue Market Share by Application (2021-2026) Table 43. Global Drugs for Schistosomiasis Revenue Market Share by Application (2027-2032) Table 44. Global Drugs for Schistosomiasis Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 45. Global Drugs for Schistosomiasis Sales by Region (2021-2026) & (M Units) Table 46. Global Drugs for Schistosomiasis Sales Market Share by Region (2021-2026) Table 47. Global Drugs for Schistosomiasis Sales Forecasted by Region (2027-2032) & (M Units) Table 48. Global Drugs for Schistosomiasis Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Drugs for Schistosomiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 50. North America Drugs for Schistosomiasis Sales by Country (2021-2026) & (M Units) Table 51. North America Drugs for Schistosomiasis Sales by Country (2027-2032) & (M Units) Table 52. Europe Drugs for Schistosomiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 53. Europe Drugs for Schistosomiasis Sales by Country (2021-2026) & (M Units) Table 54. Europe Drugs for Schistosomiasis Sales by Country (2027-2032) & (M Units) Table 55. Asia Pacific Drugs for Schistosomiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 56. Asia Pacific Drugs for Schistosomiasis Sales by Country (2021-2026) & (M Units) Table 57. Asia Pacific Drugs for Schistosomiasis Sales by Country (2027-2032) & (M Units) Table 58. South America, Middle East and Africa Drugs for Schistosomiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 59. South America, Middle East and Africa Drugs for Schistosomiasis Sales by Country (2021-2026) & (M Units) Table 60. South America, Middle East and Africa Drugs for Schistosomiasis Sales by Country (2027-2032) & (M Units) Table 61. Global Drugs for Schistosomiasis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Drugs for Schistosomiasis Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Drugs for Schistosomiasis Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Drugs for Schistosomiasis Revenue Market Share by Region (2021-2026) Table 65. Global Drugs for Schistosomiasis Revenue Market Share by Region (2027-2032) Table 66. Shin Poong Company Information Table 67. Shin Poong Business Overview Table 68. Shin Poong Drugs for Schistosomiasis Sales (M Units), Price (USD/K Units), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Shin Poong Drugs for Schistosomiasis Product Portfolio Table 70. Shin Poong Recent Development Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck Drugs for Schistosomiasis Sales (M Units), Price (USD/K Units), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Merck Drugs for Schistosomiasis Product Portfolio Table 75. Merck Recent Development Table 76. Bayer Company Information Table 77. Bayer Business Overview Table 78. Bayer Drugs for Schistosomiasis Sales (M Units), Price (USD/K Units), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Bayer Drugs for Schistosomiasis Product Portfolio Table 80. Bayer Recent Development Table 81. EIPICO Company Information Table 82. EIPICO Business Overview Table 83. EIPICO Drugs for Schistosomiasis Sales (M Units), Price (USD/K Units), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. EIPICO Drugs for Schistosomiasis Product Portfolio Table 85. EIPICO Recent Development Table 86. Chandra Bhagat Pharma Company Information Table 87. Chandra Bhagat Pharma Business Overview Table 88. Chandra Bhagat Pharma Drugs for Schistosomiasis Sales (M Units), Price (USD/K Units), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Chandra Bhagat Pharma Drugs for Schistosomiasis Product Portfolio Table 90. Chandra Bhagat Pharma Recent Development Table 91. Taj Pharmaceuticals Company Information Table 92. Taj Pharmaceuticals Business Overview Table 93. Taj Pharmaceuticals Drugs for Schistosomiasis Sales (M Units), Price (USD/K Units), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Taj Pharmaceuticals Drugs for Schistosomiasis Product Portfolio Table 95. Taj Pharmaceuticals Recent Development Table 96. Key Raw Materials Table 97. Raw Materials Key Suppliers Table 98. Drugs for Schistosomiasis Distributors List Table 99. Drugs for Schistosomiasis Customers List Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Drugs for Schistosomiasis Product Image Figure 2. Global Drugs for Schistosomiasis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Schistosomiasis Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Schistosomiasis Sales (2021-2032) & (M Units) Figure 5. Global Drugs for Schistosomiasis Average Price (USD/K Units) & (2021-2032) Figure 6. Global Top 5 and 10 Drugs for Schistosomiasis Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Praziquantel Image Figure 9. Oxamniquine Image Figure 10. Other Image Figure 11. Global Drugs for Schistosomiasis Sales by Type (2021 VS 2025 VS 2032) & (M Units) Figure 12. Global Drugs for Schistosomiasis Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Drugs for Schistosomiasis Sales Market Share by Type (2021-2032) Figure 14. Global Drugs for Schistosomiasis Revenue by Type (2021 VS 2025 VS 2032) & (M Units) Figure 15. Global Drugs for Schistosomiasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Drugs for Schistosomiasis Revenue Market Share by Type (2021-2032) Figure 17. S. haematobium Image Figure 18. S. mansoni Image Figure 19. S. japonicum Image Figure 20. S. mekongi Image Figure 21. S. intercalatum Image Figure 22. Global Drugs for Schistosomiasis Sales by Application (2021 VS 2025 VS 2032) & (M Units) Figure 23. Global Drugs for Schistosomiasis Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Drugs for Schistosomiasis Sales Market Share by Application (2021-2032) Figure 25. Global Drugs for Schistosomiasis Revenue by Application (2021 VS 2025 VS 2032) & (M Units) Figure 26. Global Drugs for Schistosomiasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Drugs for Schistosomiasis Revenue Market Share by Application (2021-2032) Figure 28. North America Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 29. North America Drugs for Schistosomiasis Sales Market Share by Country (2021-2032) Figure 30. U.S. Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 31. Canada Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 32. Mexico Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 33. Europe Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 34. Europe Drugs for Schistosomiasis Sales Market Share by Country (2021-2032) Figure 35. Germany Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 36. France Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 37. U.K. Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 38. Italy Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 39. Netherlands Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 40. Asia Pacific Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 41. Asia Pacific Drugs for Schistosomiasis Sales Market Share by Country (2021-2032) Figure 42. China Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 43. Japan Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 44. South Korea Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 45. Southeast Asia Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 46. India Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 47. Australia Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 48. South America, Middle East and Africa Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 49. South America, Middle East and Africa Drugs for Schistosomiasis Sales Market Share by Country (2021-2032) Figure 50. Brazil Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 51. South Africa Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 52. Saudi Arabia Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 53. Turkey Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 54. Argentina Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 55. UAE Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 56. Egypt Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 57. Chile Drugs for Schistosomiasis Sales and Growth Rate (2021-2032) & (M Units) Figure 58. Global Drugs for Schistosomiasis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Drugs for Schistosomiasis Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Drugs for Schistosomiasis Revenue (2021-2032) & (US$ Million) Figure 61. North America Drugs for Schistosomiasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Drugs for Schistosomiasis Revenue (2021-2032) & (US$ Million) Figure 63. Europe Drugs for Schistosomiasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Drugs for Schistosomiasis Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Drugs for Schistosomiasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Drugs for Schistosomiasis Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Drugs for Schistosomiasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Drugs for Schistosomiasis Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Drugs for Schistosomiasis Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Praziquantel
  • Oxamniquine
  • Other
Applications
  • S. haematobium
  • S. mansoni
  • S. japonicum
  • S. mekongi
  • S. intercalatum
Companies covered
  • Shin Poong
  • Merck
  • Bayer
  • EIPICO
  • Chandra Bhagat Pharma
  • Taj Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for Schistosomiasis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for Schistosomiasis Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Drugs for Schistosomiasis Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Drugs for Schistosomiasis Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Drugs for Schistosomiasis Market Dynamics
  1. 2.1 Drugs for Schistosomiasis Industry Trends
  2. 2.2 Drugs for Schistosomiasis Industry Drivers
  3. 2.3 Drugs for Schistosomiasis Industry Opportunities and Challenges
  4. 2.4 Drugs for Schistosomiasis Industry Restraints
3 Drugs for Schistosomiasis Market by Manufacturers
  1. 3.1 Global Drugs for Schistosomiasis Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Drugs for Schistosomiasis Sales by Manufacturers (2021-2026)
  3. 3.3 Global Drugs for Schistosomiasis Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Drugs for Schistosomiasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs for Schistosomiasis Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Drugs for Schistosomiasis Manufacturers, Product Type & Application
  7. 3.7 Global Drugs for Schistosomiasis Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs for Schistosomiasis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs for Schistosomiasis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs for Schistosomiasis Tier 1, Tier 2, and Tier 3
4 Drugs for Schistosomiasis Market by Type
  1. 4.1 Drugs for Schistosomiasis Type Introduction
  2. 4.1.1 Praziquantel
  3. 4.1.2 Oxamniquine
  4. 4.1.3 Other
  5. 4.2 Global Drugs for Schistosomiasis Sales by Type
  6. 4.2.1 Global Drugs for Schistosomiasis Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs for Schistosomiasis Sales by Type (2021-2032)
  8. 4.2.3 Global Drugs for Schistosomiasis Sales Market Share by Type (2021-2032)
  9. 4.3 Global Drugs for Schistosomiasis Revenue by Type
  10. 4.3.1 Global Drugs for Schistosomiasis Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Drugs for Schistosomiasis Revenue by Type (2021-2032)
  12. 4.3.3 Global Drugs for Schistosomiasis Revenue Market Share by Type (2021-2032)
5 Drugs for Schistosomiasis Market by Application
  1. 5.1 Drugs for Schistosomiasis Application Introduction
  2. 5.1.1 S. haematobium
  3. 5.1.2 S. mansoni
  4. 5.1.3 S. japonicum
  5. 5.1.4 S. mekongi
  6. 5.1.5 S. intercalatum
  7. 5.2 Global Drugs for Schistosomiasis Sales by Application
  8. 5.2.1 Global Drugs for Schistosomiasis Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Drugs for Schistosomiasis Sales by Application (2021-2032)
  10. 5.2.3 Global Drugs for Schistosomiasis Sales Market Share by Application (2021-2032)
  11. 5.3 Global Drugs for Schistosomiasis Revenue by Application
  12. 5.3.1 Global Drugs for Schistosomiasis Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Drugs for Schistosomiasis Revenue by Application (2021-2032)
  14. 5.3.3 Global Drugs for Schistosomiasis Revenue Market Share by Application (2021-2032)
6 Global Drugs for Schistosomiasis Sales by Region
  1. 6.1 Global Drugs for Schistosomiasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Schistosomiasis Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for Schistosomiasis Sales by Region (2021-2026)
  4. 6.2.2 Global Drugs for Schistosomiasis Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for Schistosomiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Drugs for Schistosomiasis Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Drugs for Schistosomiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Drugs for Schistosomiasis Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Drugs for Schistosomiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Drugs for Schistosomiasis Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Drugs for Schistosomiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Drugs for Schistosomiasis Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Drugs for Schistosomiasis Revenue by Region
  1. 7.1 Global Drugs for Schistosomiasis Revenue by Region
  2. 7.1.1 Global Drugs for Schistosomiasis Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Drugs for Schistosomiasis Revenue by Region (2021-2026)
  4. 7.1.3 Global Drugs for Schistosomiasis Revenue by Region (2027-2032)
  5. 7.1.4 Global Drugs for Schistosomiasis Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Drugs for Schistosomiasis Revenue (2021-2032)
  8. 7.2.2 North America Drugs for Schistosomiasis Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Drugs for Schistosomiasis Revenue (2021-2032)
  11. 7.3.2 Europe Drugs for Schistosomiasis Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Drugs for Schistosomiasis Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Drugs for Schistosomiasis Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Drugs for Schistosomiasis Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Drugs for Schistosomiasis Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Shin Poong
  2. 8.1.1 Shin Poong Company Information
  3. 8.1.2 Shin Poong Business Overview
  4. 8.1.3 Shin Poong Drugs for Schistosomiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Shin Poong Drugs for Schistosomiasis Product Portfolio
  6. 8.1.5 Shin Poong Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Drugs for Schistosomiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Drugs for Schistosomiasis Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Drugs for Schistosomiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Drugs for Schistosomiasis Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 EIPICO
  20. 8.4.1 EIPICO Company Information
  21. 8.4.2 EIPICO Business Overview
  22. 8.4.3 EIPICO Drugs for Schistosomiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 EIPICO Drugs for Schistosomiasis Product Portfolio
  24. 8.4.5 EIPICO Recent Developments
  25. 8.5 Chandra Bhagat Pharma
  26. 8.5.1 Chandra Bhagat Pharma Company Information
  27. 8.5.2 Chandra Bhagat Pharma Business Overview
  28. 8.5.3 Chandra Bhagat Pharma Drugs for Schistosomiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Chandra Bhagat Pharma Drugs for Schistosomiasis Product Portfolio
  30. 8.5.5 Chandra Bhagat Pharma Recent Developments
  31. 8.6 Taj Pharmaceuticals
  32. 8.6.1 Taj Pharmaceuticals Company Information
  33. 8.6.2 Taj Pharmaceuticals Business Overview
  34. 8.6.3 Taj Pharmaceuticals Drugs for Schistosomiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Taj Pharmaceuticals Drugs for Schistosomiasis Product Portfolio
  36. 8.6.5 Taj Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for Schistosomiasis Value Chain Analysis
  2. 9.1.1 Drugs for Schistosomiasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for Schistosomiasis Production Mode & Process
  6. 9.2 Drugs for Schistosomiasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for Schistosomiasis Distributors
  9. 9.2.3 Drugs for Schistosomiasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst